Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
F 2.0494 -3.33% -0.07
XBIO closed down 4.5 percent on Monday, September 27, 2021, on 21 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical XBIO trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup -3.33%
Reversal New Lows Setup Bearish Swing Setup -3.33%
Outside Day Range Expansion -3.33%
Wide Bands Range Expansion -3.33%
Down 3 Days in a Row Weakness -3.33%
Oversold Stochastic Weakness -3.33%
Narrow Range Bar Range Contraction -7.68%
Wide Bands Range Expansion -7.68%
Oversold Stochastic Weakness -7.68%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -8.51%
Older End-of-Day Signals for XBIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 1 hour ago
Down 3% about 5 hours ago
Reversal New Lows Entry about 5 hours ago
Fell Below Previous Day's Low about 5 hours ago
Down 2 % about 5 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Xenetic Biosciences, Inc. Description

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Pharmaceutical Products Acute Myeloid Leukemia FDA Dialysis Kidney Disease Chronic Kidney Disease Anemia Drug Therapies Endometrial Cancer Platform Technologies Growth Factors Refractory Acute Myeloid Leukemia Erythropoietin

Is XBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.85
52 Week Low 0.76
Average Volume 12,484,328
200-Day Moving Average 2.43
50-Day Moving Average 2.93
20-Day Moving Average 2.51
10-Day Moving Average 2.29
Average True Range 0.23
ADX 20.21
+DI 15.55
-DI 24.43
Chandelier Exit (Long, 3 ATRs) 2.57
Chandelier Exit (Short, 3 ATRs) 2.77
Upper Bollinger Bands 3.04
Lower Bollinger Band 1.98
Percent B (%b) 0.13
BandWidth 42.09
MACD Line -0.22
MACD Signal Line -0.19
MACD Histogram -0.0262
Fundamentals Value
Market Cap 13.35 Million
Num Shares 6.3 Million
EPS -12.32
Price-to-Earnings (P/E) Ratio -0.17
Price-to-Sales 22.59
Price-to-Book 0.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.57
Resistance 3 (R3) 2.60 2.49 2.49
Resistance 2 (R2) 2.49 2.37 2.47 2.47
Resistance 1 (R1) 2.30 2.30 2.24 2.27 2.44
Pivot Point 2.19 2.19 2.16 2.17 2.19
Support 1 (S1) 2.00 2.07 1.95 1.97 1.80
Support 2 (S2) 1.89 2.00 1.87 1.77
Support 3 (S3) 1.70 1.89 1.75
Support 4 (S4) 1.67